Clinical Trial Detail

NCT ID NCT02499835
Title Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Wisconsin, Madison
Indications

prostate adenocarcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.